Bronchitol available to named patients
Tuesday, 17 June, 2008
Pharmaxis (ASX: PXS) will soon be distributing its Bronchitol drug on a named patient basis through UK company IDIS.
Under the arrangement doctors can - through IDIS - prescribe Bronchitol to patients not currently undergoing clinical trials of the drug.
Patients who participate in a named patient program are warned that a drug may have unexpected side-effects, and their doctors are generally indemnified from liability as a result of this disclaimer.
The programs are generally used to allow patients with chronic illnesses access to drugs which can potentially help even in countries where the drug has not yet been cleared for sale. It is particularly used in cases where there is no satisfactory alternative available.
Bronchitol is an inhalant spray aimed at cystic fibrosis and bronchiectasis.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
